Gautham Marigowda
Overview
Explore the profile of Gautham Marigowda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
3072
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D, et al.
N Engl J Med
. 2019 Nov;
381(19):1809-1819.
PMID: 31697873
Background: Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of...
2.
Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E, et al.
Lancet
. 2019 Nov;
394(10212):1940-1948.
PMID: 31679946
Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector...
3.
Taylor-Cousar J, Mall M, Ramsey B, McKone E, Tullis E, Marigowda G, et al.
ERJ Open Res
. 2019 Jun;
5(2).
PMID: 31218221
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator gene () that result in diminished quantity and/or function of the CFTR anion channel. , the most...
4.
McNamara J, McColley S, Marigowda G, Liu F, Tian S, Owen C, et al.
Lancet Respir Med
. 2019 Jan;
7(4):325-335.
PMID: 30686767
Background: The efficacy, safety, and tolerability of lumacaftor and ivacaftor are established in patients aged 6 years and older with cystic fibrosis, homozygous for the F508del-CFTR mutation. We assessed the...
5.
Flume P, Suthoff E, Kosinski M, Marigowda G, Quittner A
J Cyst Fibros
. 2018 Dec;
18(5):737-742.
PMID: 30587335
Background: We explored the time-dependent impact of pulmonary exacerbations (PEx) on health-related quality of life (HRQoL) using Cystic Fibrosis Questionnaire-Revised (CFQ-R) data from 2 large cystic fibrosis (CF) trials. Methods:...
6.
Keating D, Marigowda G, Burr L, Daines C, Mall M, McKone E, et al.
N Engl J Med
. 2018 Oct;
379(17):1612-1620.
PMID: 30334692
Background: VX-445 is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore Phe508del CFTR protein function in patients with cystic fibrosis when administered with tezacaftor and ivacaftor...
7.
Kissner D, LeFlore Y, Narayan S, Marigowda G, Simard C, Le Camus C
J Cyst Fibros
. 2018 Sep;
17(6):e51-e53.
PMID: 30217546
No abstract available.
8.
McColley S, Konstan M, Ramsey B, Elborn J, Boyle M, Wainwright C, et al.
J Cyst Fibros
. 2018 Aug;
18(1):94-101.
PMID: 30146268
Background: Improved lung function and fewer pulmonary exacerbations (PEx) were observed with lumacaftor/ivacaftor (LUM/IVA) in patients with cystic fibrosis homozygous for F508del. It is unknown whether PEx reduction extends to...
9.
Taylor-Cousar J, Jain M, Barto T, Haddad T, Atkinson J, Tian S, et al.
J Cyst Fibros
. 2017 Nov;
17(2):228-235.
PMID: 29126871
Objective: Evaluation of the safety, tolerability, and efficacy of lumacaftor/ivacaftor in patients with cystic fibrosis (CF) with severe lung disease. Methods: Patients with CF 12 years of age and older,...
10.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, et al.
Lancet Respir Med
. 2017 Jun;
5(7):557-567.
PMID: 28606620
Background: Lumacaftor and ivacaftor combination treatment showed efficacy in patients aged 12 years or older with cystic fibrosis homozygous for F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in placebo-controlled studies and...